fouremm wrote - Long ago Don was telling us that these are much smaller and much cheaper trials and that they would serve as “inflection points” for RVX stock along the road to completion of BETOnMACE. IMO being unable to progress with these trials leaves RVX looking very much like a one trick pony with inept management that is seemingly capable of producing little more than hot air. 

I agree.

1. We have paid analyst's reports out there valuing RVX at the $5 range. We have the independent Beacon Securities David Kideckel, PhD, valuing RVX at $8.55.
2. We have 5 positive DSMB reports.
3. We have incredible post hoc findings from ASSURE.
4. We have strong results from SUSTAIN released Aug 28, 2012. MUNICH and CALGARY, Aug. 28, 2012 /CNW/ - Resverlogix Corp. (TSX: RVX) today announced that the BET protein inhibitor RVX-208 significantly increased HDL-C (p=0.001), the primary endpoint of the SUSTAIN trial, a phase 2b clinical study. SUSTAIN also successfully met secondary endpoints, showed increases in levels of Apo-AI (p=0.002) and large HDL particles (p=0.02), both believed to be important factors in enhancing reverse cholesterol transport activity. The SUSTAIN trial also showed that increases in alanine aminotransferase (ALT) reported in previous trials were infrequent and transient with no new increases observed beyond week 12 of the 24-week trial.
5. We also have independent research findings on retinal, MD, etc.
6. We have a very hot biotech investment market in the USA.
7. I suppose the $8.55 - $2 (approx share price) = $6.55 could be considered the "Don Discount Factor".

I am obviously very frustrated at Don not being capable of establishing the value of this company. I sure hope for all of us that Don has a great big rabbit to pull out of a hat sometime soon. I can't imaging what it will be.

I'm certain the financing will happen (just my opinion based on the past) but my opinion is that Don is now negotiating while on his hands and knees.

In the past Don (or Dr Wong) has been able to bring in Eastern Capital and other capital companies. I sense that one of Don's weaknesses is that he does not understand the stock markets and their potential to build value in this company. No shame in that but CEOs need to recognize their weaknesses and bring in the talent to do the job.

Oh well, we are where we are. History does not suggest a strong future until perhaps a positive FA happens whenever it happens.

Yet, many good things could happen...licensing out of trials, new regional deals, etc.

GLTA

Toinv